SAN FRANCISCO – It's impossible to imagine the biotech space without monoclonal antibodies. A recent report by Deloitte Recap LLC showed that about a third of marketed mAbs in 2009 hit blockbuster status, and experts are predicting that in a few years, the top-selling drugs will be Roche AG's Avastin (bevacizumab) and Abbott's Humira (adalimumab).